amphotericin B


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to amphotericin B: liposomal amphotericin B

am·pho·ter·i·cin B

(ăm′fə-tĕr′ĭ-sĭn)
n.
An antibiotic, C47H73NO17, derived from strains of the actinomycete Streptomyces nodosus and used to treat systemic fungal infections.

Translations

amphotericin B

n anfotericina B
References in periodicals archive ?
Results: Biochemical and histopathological analysis showed significant kidney injury in rabbits exposed to acute nephrotoxic doses of amphotericin B and cyclosporine.
Amphotericin B and surgery, in selected cases, are major treatment options.
Key Words: Amphotericin B Nephrotoxicity Nigella sativa Mice Serum urea and creatinine.
The Cryptococcal Optimal ART Timing (COAT) trial [13] conducted in Uganda and SA was designed to address these questions, randomising patients treated with amphotericin-based induction (1 mg/kg/day amphotericin B with 800 mg/day fluconazole) to early (1-2 weeks, median 8 days) v.
5) For non-meningeal disseminated disease, an oral azole is first line, but amphotericin B can be utilized if there is vertebral involvement or rapid deterioration of clinical status.
5) However, access to the preferred drugs, amphotericin B and flucytosine, is a challenge, as highlighted by a rapid survey of MSF HIV/AIDS programmes in 9 countries.
neoformans isolates that are not susceptible to amphotericin B, fluconazole, flucytosine, or itraconazole during treatment.
An article recently published on this topic in Dynamics, the Journal of the Canadian Association of Critical Care Nurses (entitled "ALERT: Mix-ups between conventional and lipid formulations of amphotericin B can be extremely dangerous.
Intravenous amphotericin is currently marketed in Canada as conventional (non-lipid) amphotericin B (Fungizone[R]) and as lipid formulations (AmBisome[R]--a liposomal formulation, and Abelcet[R]--a lipid complex formulation).
Antifungal therapy is not recommended for primary pulmonary coccidioidomycosis in immunocompetent patients who have no risk factors for dissemination, while patients with disseminated infection should be treated with an extended-spectrum triazole, according to the guidelines, which also specify that critically ill patients with disseminated paracocddioidomycosis should be treated initially with amphotericin B, followed by ketoconazole, itraconazole, or sulfadiazine.
The aim of this study was to find an alternative for amphotericin B currently used in treatment of fungal infections.
To show comparable blood levels to existing commercial versions of Amphotericin B, which are administered via IV infusion, is exciting to us as there is a clear commercial medical need for an oral antifungal with the strength and breadth of action of Amphotericin.